Non‐small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about ninety per cent of lung cancers in the UK. A small proportion of NSCLC tumours have a genetic change in a gene called c‐METexon14. When NSCLC tumours have advanced or spread to other organs there are very limited treatments available.
Crizotinib is an anticancer drug that can be taken up to twice a day orally as capsules. Crizotinib works by blocking the growth and spread of cancer cells that have c‐METexon14 changes to other parts of the body. Crizotinib is already approved for the treatment of a subtype of advanced NSCLC with a different genetic change (ALK mutations) in people that have been previously treated with chemotherapy. If approved for this new indication, crizotinib has the potential to prolong survival for patients with NSCLC and c‐MET gene alteration that have advanced or spread to other organs, for which no other treatment is available apart from best supportive care.
Ixazomib citrate is a novel oral medicinal product that is already licensed in the UK for the treatment of MM in patients who have received at least one prior therapy (in combination with lenalidomide and dexamethasone). Ixazomib citrate offers the potential advantage over similar medicines in its class of being more effective in its anticancer activity, less toxic (reduced side effects) and more convenient to administer (through its weekly oral dosing). If approved as maintenance therapy following stem cell transplant in newly diagnosed MM patients, ixazomib citrate has the potential to improve the success rates of treatment by improving progression free survival and overall survival as well as presenting a more convenient way of administration that allows long term administration and improvement of patients’ quality of life.